Eledon Pharmaceuticals, Inc. ELDN · Stock Open Eledon Pharmaceuticals, Inc. in new tab
Eledon Pharmaceuticals, Inc. Analysis (ELDN)
Is Eledon Pharmaceuticals, Inc. a good investment? Eledon Pharmaceuticals, Inc. (ELDN) is currently trading at 2.69 USD. Market analysts have a consensus price target of 9.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Eledon Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 13, 2026. The market consensus estimate for Forward EPS is -0.77.
Investor FAQ
Does Eledon Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Eledon Pharmaceuticals, Inc.?
Eledon Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 13, 2026. The company currently has a trailing EPS of -0.90.
Company Profile
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
| Split Date | Split Ratio to 1 |
|---|---|
| May 11, 2017 | 0.11 |
| Oct. 5, 2020 | 0.06 |
Community Discussion